Name: Lung Cancer Therapy Market Size and Forecasts (2020-2030)
SKU: TIPRE00030093
Availability: InStock

Lung Cancer Therapy Market Size and Forecasts (2020-2030)

Lung Cancer Therapy Market Size and Forecasts (2020 – 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Therapy Type (Noninvasive and Minimally Invasive), Indication (Non-Small Cell Lung Cancer and Small Cell Lung Cancer), End User (Hospitals, Oncology Clinics, Research Centers, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)

Send Enquiry

Item ID: TIPRE00030093 Category: Library Tag: Medical Devices; number of pages: 206; status: published; publishing date: 30-Oct-23

$3,185 – $5,985

Description

The lung cancer therapy market is expected to grow from US$ 31.018 billion in 2022 to US$ 80.493 billion by 2030; it is anticipated to record a CAGR of 12.7% from 2022 to 2030.

Targeted therapy, a type of personalized medicine, is a combination of two or more drugs, designed to directly target the cancerous cells. Therapies such as ablation and chemotherapy destroy healthy cells along with infected cells, which can affect the overall patient condition. Targeted therapy is designed in a way to selectively kill cancerous cells, keeping the function of healthy cells unhampered. With recent developments in medical technologies, focus on the use of targeted therapy for the treatment of lung cancer is increasing notably. Scientists are focusing on studying lung cancer cell mutations that are responsible for driving the uncontrolled growth of cancerous cells. In May 2021, the US Food and Drug Administration approved Lumakras (sotorasib), the first treatment for adult non-small cell lung cancer patients. This therapy is given to patients who have KRAS G12C mutation and have received at least one prior systemic therapy. The companies are using biomarkers such as EGFR, ALK, ROS1, and KRAS to develop targeted therapies, which help detect the type of mutation in the cancerous cells. Thus, the increasing focus of companies on the development of targeted therapies, coupled with the growing awareness about their benefits to lung cancer patients, is expected to bring new trends in the lung cancer therapy market in the coming years.

Government Initiatives for Screening and Treatment of Lung Cancer drives the growth the Lung Cancer Therapy Market

According to an article published by Johnson & Johnson, lung cancer is a leading cause of cancer mortality in the world, and it is generally detected in the later stages. In the initial stages, people with lung cancer show no prominent symptoms, and therefore, in almost 50% of the detected cases, cancer has already reached the metastasis stage. In response to the seriousness of this condition, governments of various countries are focusing on introducing initiatives for encouraging early detection and screening, followed by providing early treatment for lung cancer.

As per United States Preventive Services Task Force (USPSTF), people from the age range of 50–80 with a smoking history of 20 packs per year, either presently smoking or having quit within the last 15 years, are more susceptible to developing lung cancer in the US. Hence, the United States Preventive Services Task Force (USPSTF) recommends these people undergo low-dose computed tomography (LDCT) screening for lung cancer every year to ensure the early detection of lung cancer. In addition, in July 2022, the Biden Administration in the US introduced a new model that aims to improve cancer care and lower the treatment cost for patients who are covered under Medicare services.

In July 2021, Cancer Australia partnered with the Department of Health and Aged Care to evaluate the feasibility of a lung cancer screening program in Australia. After obtaining positive results of the feasibility assessment, in May 2023, the Department of Health and Aged Care, the Government of Australia, declared an investment of US$ 263.8 million for 2023–2024 for the implementation of the National Lung Cancer Screening Program across the country. Through this program, the Department of Health and Aged Care focuses on the prevention and early detection of lung cancer. Further, the Beating Cancer Plan introduced by the European Health Union aims to tackle the entire disease pathway by focusing on prevention, treatment, and care of lung cancer patients.

Thus, an upsurge in initiatives taken by governments for the early detection and proper treatment of lung cancer patients fuels the growth of the lung cancer therapy market.

The lung cancer therapy market is divided on the basis of therapy type, indication, end user, and geography. The lung cancer therapy market, by vaccine type, is bifurcated into noninvasive and minimally invasive. The minimally invasive segment is further classified into radiofrequency ablation, microwave ablation, thermal ablation, cryoablation, chemical ablation, photodynamic ablation, and others. The lung cancer therapy market, by indication, is segmented into non-small cell lung cancer and small cell lung cancer. The market, by end user, is segmented into hospitals, oncology clinics, research centers, and others.

Based on geography, the market is segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. North America held the largest market share of the lung cancer therapy market. North America accounts for a significant market share owing to the growing incidences of lung cancer cases due to increase in smoking, consumption of tobacco, and increase in air pollution due to industrialization. The growth of the lung cancer therapy market in the US is mainly driven by the increasing incidence of lung cancer cases, product launches, and government initiatives. Lung cancer is the second most common cancer in the US. As per the American Cancer Society, Inc., as of 2023, ~238,340 adults (117,550 men and 120,790 women) in the US have been diagnosed with lung cancer; also, ~127,070 (67,160 in men and 59,910 in women) have succumbed to death due to the disease. Lung cancer accounts for 1 in 5 of all cancer deaths, making it a leading cause of cancer death in the US. As per the same source, NSCLC accounts for 81% of all lung cancer diagnoses. Thus, the increasing incidence of lung cancer in the country fuels the growth of the US lung cancer therapy market.

Various product launches for the treatment of lung cancer by companies are also bolstering the market growth. For instance, in May 2021, the US FDA approved Lumakras (sotorasib) as the first targeted therapy for adult non-small cell lung cancer patients. This is the first targeted therapy that is approved for tumors with KRAS mutation, which reports ~25% of mutations in non-small cell lung cancer (NSCLC). Moreover, in May 2021, the US FDA granted accelerated approval to amivantamab-vmjw (Rybrevant), a bispecific antibody directed against epidermal growth factor (EGF) and MET receptors, for adult patients with locally advanced or metastatic NSCLC that comprises EGFR exon 20 insertion mutations.

As per the report published in the whitehouse.gov, the official website of the White House, managed by the Office of Digital Strategy in May 2023, the Association of Community Cancer Centers (ACCC) and AstraZeneca entered into a partnership for the development and implementation of person-centered and sustainable approaches to drive lung cancer screening in rural America through “Rural Appalachian Lung Cancer Screening Initiative.” The cancer mortality rate in the Appalachian region, including all of West Virginia and a few parts of 12 other states, is 10% higher than that of the rest of the US. This initiative aims to double the five-year survival rate for lung cancer. Such initiatives are contributing to the growth of the lung cancer therapy market in the US.

ClinicalTrails.com, Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), and United States Preventive Services Task Force (USPSTF) are a few key primary and secondary sources referred to while preparing the report on the lung cancer therapy market.

Summary Info

Industry:	Medical Devices
Pricing options:	Single User License, Site License, Enterprise License
Geographical coverage:	Global
Year of Publication:	2023

Minimally Invasive Segment, by Therapy Type to Account Larger Share in Lung Cancer Therapy Market during 2022–2030

According to our latest study on “Lung Cancer Therapy Market Forecast to 2030 –Global Analysis – Therapy Type, Indication, and End User,” the market is expected to grow from US$ 31.018 billion in 2022 and is expected to reach US$ 80.493 billion by 2030; it is anticipated to record a CAGR of 12.7% from 2022 to 2030. The report highlights the key factors driving the lung cancer therapy market growth and prominent players with their developments in the market.

The lung cancer therapy market size is expanding with the rising cases of lung cancer, and the increasing habit of smoking and tobacco consumption in countries such as the UK, Germany, the US, and India. ~48,000 people get diagnosed with lung cancer, and ~35,000 people die yearly because of the disease in the UK. Smoking is the most common cause of lung cancer, while other causes include passive smoking and exposure to certain gases and chemicals. Currently, every fourth man (~27.0%) and every fifth woman (~21%) in Germany smokes regularly. The current landscape for lung cancer therapies is promising, with multiple drug approvals, a rich pipeline, and many ongoing clinical trials. Multiple lung cancer therapies are in various stages of clinical development; pharmaceutical giants are working to expand their pipeline, which is a major opportunity prevailing in the lung cancer therapy market.

The lung cancer therapy market, by vaccine type, is segmented into non-invasive and minimally invasive. Minimally Invasive segment is further classified into radiofrequency ablation, microwave ablation, thermal ablation, cryoablation, chemical ablation, photodynamic ablation, and others. In 2022, the non-invasive therapy segment held the largest market share by product. However, minimally invasive segment is expected to grow at the fastest rate in the coming years. Radiation therapy, chemotherapy, and targeted therapy are the major types of non-invasive therapy for lung cancer. Radiation lung cancer therapy uses high energy and powerful X-rays to eliminate the cancerous cells, control their growth, and stop their spread in the lung. Radiation therapy is used before and after surgeries to shrink the tumor before surgery and kill the persistent cancer cells after the surgery. In chemotherapy, drugs are used to kill the new or existing cancerous cells in the lungs. Chemotherapy is considered an important treatment for lung cancer. According to the article “Chemotherapy Statistics,” in 2023, approximately 2% of stage 1 and 2 patients, 9% of stage 3 patients, and 27% of stage 4 patients receive chemotherapy for treatment of their lung cancer, respectively. The use of chemotherapy and radiation therapy for lung cancer is fueling the segment growth.

The lung cancer therapy market, by the indication, is segmented into non-small cell lung cancer and small cell lung cancer. In 2022, the non-small cell lung cancer segment held the largest market share by indication. Moreover, the non-small cell lung cancer segment is expected to grow at the fastest rate during the coming years. Non-small cell lung cancer (NSCLC) occurs when abnormal cells proliferate in the lung tissues. There are three primary forms of NSCLC cancer—adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Other types of NSCLC include adenosquamous carcinoma and sarcomatoid carcinoma, which are substantially less frequent in occurrence. NSCLC develops more slowly than small-cell lung cancer. It usually spreads to other parts of the patient’s body by the time it is diagnosed. Therefore, early diagnosis and treatment are crucial. According to the National Foundation for Cancer Research, NSCLC accounts for approximately 9 out of every 10 diagnoses. As per the same source, large-cell undifferentiated carcinoma lung cancer reports for ~10–15% of all NSCLC diagnoses. This type of lung cancer can originate in any part of the lung and is also known to grow and spread quickly.

Medtronic PLC, RF Medical Co Ltd, Johnson & Johnson, Merck KGaA, Sun Pharmaceutical Industries Ltd, Bioventus Inc, Meiji Seika Pharma Co Ltd, Advanz Pharma Corp, and Olympus Corp are among the leading companies operating in the global lung cancer therapy market.

Companies operating in the lung cancer therapy market adopt various organic and inorganic strategies. Organic strategies mainly include product launches and product approvals. Acquisitions, collaborations, and partnerships are among the inorganic growth strategies witnessed in the lung cancer therapy market. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall lung cancer therapy market growth. Further, acquisition and partnership strategies help them strengthen their customer base and expand their product portfolios.

A few of the significant developments by key market players are listed below.

• In October 2023, Johnson & Johnson submitted the Type II extension of indication application seeking approval of the European Medicines Agency (EMA) for the use of RYBREVANT (amivantamab) in combination with chemotherapy (carboplatin and pemetrexed) as the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) exon 20 insertion mutations.

• In December 2022, RF Medical Co Ltd announced that the FDA approved their patented MYGEN M-3004 generator and MYOBLATE radiofrequency ablation system for commercialization in the US. These devices are used to treat damaged tumors and tissues.

• May 2021, Janssen Pharmaceutical Companies of Johnson & Johnson announced that the US FDA granted the accelerated approval of RYBREVANTTM (amivantamab-vmjw) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. The drug is indicated among patients showing disease progression on or after platinum-based chemotherapy. RYBREVANTTM is the first fully-human, bispecific antibody approved for the treatment of patients with NSCLC that targets EGFR exon 20 insertion mutations, which are the third most prevalent activating EGFR mutation.

o Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the lung cancer therapy market.
o Highlights key business priorities in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in the lung cancer therapy market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth market trends and outlook coupled with the factors driving the lung cancer therapy market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.

TABLE OF CONTENTS

1. Introduction
1.1 The Research Team Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Lung Cancer Therapy Market, by Geography
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Lung Cancer Therapy Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Global PEST Analysis
5. Lung Cancer Therapy Market – Key Industry Dynamics
5.1 Market Drivers:
5.1.1 Increase in Cases of Lung Cancer
5.1.2 Government Initiatives for Screening and Treatment of Lung Cancer
5.2 Market Restraints
5.2.1 High Cost of Lung Cancer Therapy
5.3 Market Opportunities
5.3.1 Rising Number of Lung Cancer Therapy in Clinical Trials
5.4 Future Trends
5.4.1 Growing Demand for Targeted Therapy
5.5 Impact Analysis:
6. Lung Cancer Therapy Market – Global Market Analysis
6.1 Lung Cancer Therapy Market Revenue (US$ Mn), 2020 – 2030
7. Global Lung Cancer Therapy Market – Revenue and Forecast to 2030 – by Therapy Type
7.1 Overview
7.2 Lung Cancer Therapy Market Revenue Share, by Therapy Type, 2022 & 2030 (%)
7.3 Non-Invasive Therapy
7.3.1 Overview
7.3.2 Non-Invasive Therapy: Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Minimally Invasive
7.4.1 Overview
7.4.2 Minimally Invasive: Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
7.4.2.1 Global: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
8. Global Lung Cancer Therapy Market – Revenue and Forecast to 2030 – by Indication
8.1 Overview
8.2 Lung Cancer Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
8.3 Non-Small Cell Lung Cancer
8.3.1 Overview
8.3.2 Non-Small Cell Lung Cancer: Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Small Cell Lung Cancer
8.4.1 Overview
8.4.2 Small Cell Lung Cancer: Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
9. Global Lung Cancer Therapy Market – Revenue and Forecast to 2030 – by End User
9.1 Overview
9.2 Lung Cancer Therapy Market Revenue Share, by End User, 2022 & 2030 (%)
9.3 Hospitals
9.3.1 Overview
9.3.2 Hospitals: Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
9.4 Oncology Clinics
9.4.1 Overview
9.4.2 Oncology Clinics: Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
9.5 Research Centers
9.5.1 Overview
9.5.2 Research Centers: Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
9.6 Others
9.6.1 Overview
9.6.2 Others: Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
10. Lung Cancer Therapy Market – Geographical Analysis
10.1 North America Lung Cancer Therapy Market, Revenue and Forecast To 2030
10.1.1 Overview
10.1.2 North America Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.1.3 North America: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.1.3.1 North America: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.1.4 North America: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.1.5 North America: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.1.6 North America Lung Cancer Therapy Market, by Country
10.1.6.1 US
10.1.6.1.1 Overview
10.1.6.1.2 US Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.1.6.1.3 US: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.1.6.1.3.1 US: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.1.6.1.4 US: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.1.6.1.5 US: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.1.6.2 Canada
10.1.6.2.1 Overview
10.1.6.2.2 Canada Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.1.6.2.3 Canada: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.1.6.2.3.1 Canada: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.1.6.2.4 Canada: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.1.6.2.5 Canada: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.1.6.3 Mexico
10.1.6.3.1 Overview
10.1.6.3.2 Mexico Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.1.6.3.3 Mexico: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.1.6.3.3.1 Mexico: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.1.6.3.4 Mexico: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.1.6.3.5 Mexico: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.2 Europe Lung Cancer Therapy Market, Revenue and Forecast to 2030
10.2.1 Overview
10.2.2 Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.2.3 Europe: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.2.3.1 Europe: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.2.4 Europe: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.2.5 Europe: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.2.6 Europe Lung Cancer Therapy Market, by Country
10.2.6.1 UK
10.2.6.1.1 Overview
10.2.6.1.2 UK Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.1.3 UK: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.2.6.1.3.1 UK: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.2.6.1.4 UK: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.2.6.1.5 UK: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.2.6.2 Germany
10.2.6.2.1 Overview
10.2.6.2.2 Germany Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.2.3 Germany: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.2.6.2.3.1 Germany: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.2.6.2.4 Germany: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.2.6.2.5 Germany: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.2.6.3 France
10.2.6.3.1 Overview
10.2.6.3.2 France Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.3.3 France: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.2.6.3.3.1 France: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.2.6.3.4 France: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.2.6.3.5 France: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.2.6.4 Italy
10.2.6.4.1 Overview
10.2.6.4.2 Italy Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.4.3 Italy: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.2.6.4.3.1 Italy: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.2.6.4.4 Italy: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.2.6.4.5 Italy: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.2.6.5 Spain
10.2.6.5.1 Overview
10.2.6.5.2 Spain Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.5.3 Spain: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.2.6.5.3.1 Spain: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.2.6.5.4 Spain: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.2.6.5.5 Spain: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.2.6.6 Russia
10.2.6.6.1 Overview
10.2.6.6.2 Russia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.6.3 Russia: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.2.6.6.3.1 Russia: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.2.6.6.4 Russia: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.2.6.6.5 Russia: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.2.6.7 Rest of Europe
10.2.6.7.1 Overview
10.2.6.7.2 Rest of Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.2.6.7.3 Rest of Europe: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.2.6.7.3.1 Rest of Europe: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.2.6.7.4 Rest of Europe: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.2.6.7.5 Rest of Europe: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3 Asia Pacific Lung Cancer Therapy Market, Revenue and Forecast to 2030
10.3.1 Overview
10.3.2 Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.3 Asia Pacific: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.3.1 Asia Pacific: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.4 Asia Pacific: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.5 Asia Pacific: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6 Asia Pacific Lung Cancer Therapy Market, by Country
10.3.6.1 China
10.3.6.1.1 Overview
10.3.6.1.2 China Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.1.3 China: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.1.3.1 China: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.1.4 China: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.1.5 China: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.2 Japan
10.3.6.2.1 Overview
10.3.6.2.2 Japan Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.2.3 Japan: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.2.3.1 Japan: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.2.4 Japan: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.2.5 Japan: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.3 India
10.3.6.3.1 Overview
10.3.6.3.2 India Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.3.3 India: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.3.3.1 India: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.3.4 India: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.3.5 India: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.4 Australia
10.3.6.4.1 Overview
10.3.6.4.2 Australia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.4.3 Australia: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.4.3.1 Australia: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.4.4 Australia: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.4.5 Australia: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.5 South Korea
10.3.6.5.1 Overview
10.3.6.5.2 South Korea Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.5.3 South Korea: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.5.3.1 South Korea: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.5.4 South Korea: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.5.5 South Korea: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.6 Southeast Asia
10.3.6.6.1 Overview
10.3.6.6.2 Southeast Asia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.6.3 Southeast Asia: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.6.3.1 Southeast Asia: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.6.4 Southeast Asia: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.6.5 Southeast Asia: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.6.6 Singapore
10.3.6.6.6.1 Singapore Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.6.6.2 Singapore: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.6.6.2.1 Singapore: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.6.6.3 Singapore: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.6.6.4 Singapore: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.6.7 Malaysia
10.3.6.6.7.1 Malaysia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.6.7.2 Malaysia: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.6.7.2.1 Malaysia: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.6.7.3 Malaysia: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.6.7.4 Malaysia: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.6.8 Indonesia
10.3.6.6.8.1 Indonesia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.6.8.2 Indonesia: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.6.8.2.1 Indonesia: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.6.8.3 Indonesia: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.6.8.4 Indonesia: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.6.9 Vietnam
10.3.6.6.9.1 Vietnam Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.6.9.2 Vietnam: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.6.9.2.1 Vietnam: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.6.9.3 Vietnam: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.6.9.4 Vietnam: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.6.10 Cambodia
10.3.6.6.10.1 Cambodia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.6.10.2 Cambodia: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.6.10.2.1 Cambodia: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.6.10.3 Cambodia: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.6.10.4 Cambodia: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.6.11 Philippines
10.3.6.6.11.1 Philippines Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.6.11.2 Philippines: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.6.11.2.1 Philippines: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.6.11.3 Philippines: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.6.11.4 Philippines: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.6.12 Rest of Southeast Asia
10.3.6.6.12.1 Rest of Southeast Asia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.6.12.2 Rest of Southeast Asia: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.6.12.2.1 Rest of Southeast Asia: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.6.12.3 Rest of Southeast Asia: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.6.12.4 Rest of Southeast Asia: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.3.6.7 Rest of Asia Pacific
10.3.6.7.1 Overview
10.3.6.7.2 Rest of Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.3.6.7.3 Rest of Asia Pacific: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.3.6.7.3.1 Rest of Asia Pacific: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.3.6.7.4 Rest of Asia Pacific: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.3.6.7.5 Rest of Asia Pacific: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.4 Middle East & Africa Lung Cancer Therapy Market, Revenue and Forecast to 2030
10.4.1 Overview
10.4.2 Middle East & Africa Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.4.3 Middle East & Africa: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.4.3.1 Middle East & Africa: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.4.4 Middle East & Africa: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.4.5 Middle East & Africa: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.4.5.1 Middle East & Africa Lung Cancer Therapy Market, by Country
10.4.5.2 Saudi Arabia
10.4.5.2.1 Overview
10.4.5.2.2 Saudi Arabia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.4.5.2.3 Saudi Arabia: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.4.5.2.3.1 Saudi Arabia: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.4.5.2.4 Saudi Arabia: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.4.5.2.5 Saudi Arabia: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.4.5.3 South Africa
10.4.5.3.1 Overview
10.4.5.3.2 South Africa Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.4.5.3.3 South Africa: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.4.5.3.3.1 South Africa: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.4.5.3.4 South Africa: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.4.5.3.5 South Africa: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.4.5.4 UAE
10.4.5.4.1 Overview
10.4.5.4.2 UAE Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.4.5.4.3 UAE: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.4.5.4.3.1 UAE: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.4.5.4.4 UAE: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.4.5.4.5 UAE: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.4.5.5 Rest of Middle East Africa
10.4.5.5.1 Overview
10.4.5.5.2 Rest of Middle East Africa Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.4.5.5.3 Rest of Middle East Africa: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.4.5.5.3.1 Rest of Middle East Africa: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.4.5.5.4 Rest of Middle East Africa: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.4.5.5.5 Rest of Middle East Africa: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.5 South & Central America Lung Cancer Therapy Market, Revenue and Forecast to 2030
10.5.1 Overview
10.5.2 South & Central America Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.5.3 South & Central America: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.5.3.1 South & Central America: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.5.4 South & Central America: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.5.5 South & Central America: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.5.6 South & Central America Lung Cancer Therapy Market, by Country
10.5.6.1 Brazil
10.5.6.1.1 Overview
10.5.6.1.2 Brazil Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.5.6.1.3 Brazil: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.5.6.1.3.1 Brazil: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.5.6.1.4 Brazil: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.5.6.1.5 Brazil: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.5.6.2 Argentina
10.5.6.2.1 Overview
10.5.6.2.2 Argentina Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.5.6.2.3 Argentina: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.5.6.2.3.1 Argentina: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.5.6.2.4 Argentina: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.5.6.2.5 Argentina: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
10.5.6.3 Rest of South & Central America
10.5.6.3.1 Overview
10.5.6.3.2 Rest of South & Central America Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
10.5.6.3.3 Rest of South & Central America: Lung Cancer Therapy Market, by Therapy Type, 2020–2030 (US$ Million)
10.5.6.3.3.1 Rest of South & Central America: Lung Cancer Therapy Market, by Minimally Invasive, 2020–2030 (US$ Million)
10.5.6.3.4 Rest of South & Central America: Lung Cancer Therapy Market, by Indication, 2020–2030 (US$ Million)
10.5.6.3.5 Rest of South & Central America: Lung Cancer Therapy Market, by End User, 2020–2030 (US$ Million)
11. Lung Cancer Therapy Market – Industry Landscape
11.1 Overview
11.2 Growth Strategies in Lung Cancer Therapy Market
11.3 Inorganic Growth Strategies
11.3.1 Overview
11.4 Organic Growth Strategies
11.4.1 Overview
12. Company Profiles
12.1 Medtronic Plc
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 RF Medical Co Ltd
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Johnson & Johnson
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Merck KGaA
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Sun Pharmaceutical Industries Ltd
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Bioventus Inc
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Olympus Corp
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Meiji Seika Pharma Co Ltd
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Advanz Pharma Corp
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
13. Appendix
13.1 About Us
13.2 Glossary of Terms

LIST OF TABLES

Table 1. Lung Cancer Therapy Market Segmentation
Table 2. Global Lung Cancer Therapy Market, by Minimally Invasive– Revenue and Forecast to 2030 (US$ Million)
Table 3. North America Lung Cancer Therapy Market, by Therapy Type– Revenue and Forecast to 2030 (US$ Million)
Table 4. North America Lung Cancer Therapy Market, by Minimally Invasive– Revenue and Forecast to 2030 (US$ Million)
Table 5. North America Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 6. North America Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 7. US Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 8. US Lung Cancer Therapy Market, by Minimally Invasive– Revenue and Forecast to 2030 (US$ Million)
Table 9. US Lung Cancer Therapy Market, by Indication– Revenue and Forecast to 2030 (US$ Million)
Table 10. US Lung Cancer Therapy Market, by End User– Revenue and Forecast to 2030 (US$ Million)
Table 11. Canada Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 12. Canada Lung Cancer Therapy Market, by Minimally Invasive– Revenue and Forecast to 2030 (US$ Million)
Table 13. Canada Lung Cancer Therapy Market, by Indication– Revenue and Forecast to 2030 (US$ Million)
Table 14. Canada Lung Cancer Therapy Market, by End User– Revenue and Forecast to 2030 (US$ Million)
Table 15. Mexico Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 16. Mexico Lung Cancer Therapy Market, by Minimally Invasive– Revenue and Forecast to 2030 (US$ Million)
Table 17. Mexico Lung Cancer Therapy Market, by Indication– Revenue and Forecast to 2030 (US$ Million)
Table 18. Mexico Lung Cancer Therapy Market, by End User– Revenue and Forecast to 2030 (US$ Million)
Table 19. Europe Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 20. Europe Lung Cancer Therapy Market, by Minimally Invasive– Revenue and Forecast to 2030 (US$ Million)
Table 21. Europe Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 22. Europe Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 23. UK Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 24. UK Lung Cancer Therapy Market, by Minimally Invasive– Revenue and Forecast to 2030 (US$ Million)
Table 25. UK Lung Cancer Therapy Market, by Indication– Revenue and Forecast to 2030 (US$ Million)
Table 26. UK Lung Cancer Therapy Market, by End User– Revenue and Forecast to 2030 (US$ Million)
Table 27. Germany Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 28. Germany Lung Cancer Therapy Market, by Minimally Invasive– Revenue and Forecast to 2030 (US$ Million)
Table 29. Germany Lung Cancer Therapy Market, by Indication– Revenue and Forecast to 2030 (US$ Million)
Table 30. Germany Lung Cancer Therapy Market, by End User– Revenue and Forecast to 2030 (US$ Million)
Table 31. France Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 32. France Lung Cancer Therapy Market, by Minimally Invasive– Revenue and Forecast to 2030 (US$ Million)
Table 33. France Lung Cancer Therapy Market, by Indication– Revenue and Forecast to 2030 (US$ Million)
Table 34. France Lung Cancer Therapy Market, by End User– Revenue and Forecast to 2030 (US$ Million)
Table 35. Italy Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 36. Italy Lung Cancer Therapy Market, by Minimally Invasive– Revenue and Forecast to 2030 (US$ Million)
Table 37. Italy Lung Cancer Therapy Market, by Indication– Revenue and Forecast to 2030 (US$ Million)
Table 38. Italy Lung Cancer Therapy Market, by End User– Revenue and Forecast to 2030 (US$ Million)
Table 39. Spain Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 40. Spain Lung Cancer Therapy Market, by Minimally Invasive– Revenue and Forecast to 2030 (US$ Million)
Table 41. Spain Lung Cancer Therapy Market, by Indication– Revenue and Forecast to 2030 (US$ Million)
Table 42. Spain Lung Cancer Therapy Market, by End User– Revenue and Forecast to 2030 (US$ Million)
Table 43. Russia Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 44. Russia Lung Cancer Therapy Market, by Minimally Invasive– Revenue and Forecast to 2030 (US$ Million)
Table 45. Russia Lung Cancer Therapy Market, by Indication– Revenue and Forecast to 2030 (US$ Million)
Table 46. Russia Lung Cancer Therapy Market, by End User– Revenue and Forecast to 2030 (US$ Million)
Table 47. Rest of Europe Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 48. Rest of Europe Lung Cancer Therapy Market, by Minimally Invasive– Revenue and Forecast to 2030 (US$ Million)
Table 49. Rest of Europe Lung Cancer Therapy Market, by Indication– Revenue and Forecast to 2030 (US$ Million)
Table 50. Rest of Europe Lung Cancer Therapy Market, by End User– Revenue and Forecast to 2030 (US$ Million)
Table 51. Asia Pacific Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 52. Asia Pacific Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 53. Asia Pacific Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 54. Asia Pacific Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 55. China Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 56. China Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 57. China Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 58. China Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 59. Japan Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 60. Japan Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 61. Japan Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 62. Japan Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 63. India Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 64. India Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 65. India Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 66. India Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 67. Australia Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 68. Australia Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 69. Australia Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 70. Australia Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 71. South Korea Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 72. South Korea Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 73. South Korea Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 74. South Korea Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 75. Southeast Asia Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 76. Southeast Asia Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 77. Southeast Asia Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 78. Southeast Asia Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 79. Singapore Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 80. Singapore Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 81. Singapore Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 82. Singapore Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 83. Malaysia Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 84. Malaysia Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 85. Malaysia Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 86. Malaysia Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 87. Indonesia Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 88. Indonesia Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 89. Indonesia Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 90. Indonesia Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 91. Vietnam Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 92. Vietnam Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 93. Vietnam Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 94. Vietnam Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 95. Cambodia Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 96. Cambodia Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 97. Cambodia Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 98. Cambodia Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 99. Philippines Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 100. Philippines Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 101. Philippines Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 102. Philippines Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 103. Rest of Southeast Asia Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 104. Rest of Southeast Asia Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 105. Rest of Southeast Asia Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 106. Rest of Southeast Asia Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 107. Rest of Asia Pacific Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 108. Rest of Asia Pacific Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 109. Rest of Asia Pacific Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 110. Rest of Asia Pacific Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 111. Middle East & Africa Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 112. Middle East & Africa Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 113. Middle East & Africa Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 114. Middle East & Africa Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 115. Saudi Arabia Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 116. Saudi Arabia Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 117. Saudi Arabia Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 118. Saudi Arabia Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 119. South Africa Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 120. South Africa Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 121. South Africa Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 122. South Africa Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 123. UAE Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 124. UAE Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 125. UAE Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 126. UAE Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 127. Rest of Middle East Africa Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 128. Rest of Middle East Africa Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 129. Rest of Middle East Africa Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 130. Rest of Middle East Africa Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 131. South & Central America Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 132. South & Central America Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 133. South & Central America Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 134. South & Central America Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 135. Brazil Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 136. Brazil Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 137. Brazil Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 138. Brazil Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 139. Argentina Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 140. Argentina Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 141. Argentina Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 142. Argentina Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 143. Rest of South & Central America Lung Cancer Therapy Market, by Therapy Type – Revenue and Forecast to 2030 (US$ Million)
Table 144. Rest of South & Central America Lung Cancer Therapy Market, by Minimally Invasive – Revenue and Forecast to 2030 (US$ Million)
Table 145. Rest of South & Central America Lung Cancer Therapy Market, by Indication – Revenue and Forecast to 2030 (US$ Million)
Table 146. Rest of South & Central America Lung Cancer Therapy Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 147. Recent Inorganic Growth Strategies in the Lung Cancer Therapy Market
Table 148. Recent Organic Growth Strategies in Lung Cancer Therapy Market
Table 149. Glossary of Terms, Lung Cancer Therapy Market

LIST OF FIGURES

Figure 1. Lung Cancer Therapy Market Segmentation, By Geography
Figure 2. Global – PEST Analysis
Figure 3. Lung Cancer Therapy Market – Key Industry Dynamics
Figure 4. Impact Analysis of Drivers and Restraints
Figure 5. Lung Cancer Therapy Market Revenue (US$ Mn), 2020 – 2030
Figure 6. Lung Cancer Therapy Market Revenue, Geography (US$ Mn), 2022 – 2030
Figure 7. Lung Cancer Therapy Market Revenue Share, by Therapy Type, 2022 & 2030 (%)
Figure 8. Non-Invasive Therapy: Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. Minimally Invasive: Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 10. Lung Cancer Therapy Market Revenue Share, by Indication, 2022 & 2030 (%)
Figure 11. Non-Small Cell Lung Cancer: Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. Small Cell Lung Cancer: Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Lung Cancer Therapy Market Revenue Share, End User, 2022 & 2030 (%)
Figure 14. Hospitals: Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 15. Oncology Clinics: Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 16. Research Centers: Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 17. Others: Lung Cancer Therapy Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. North America: Lung Cancer Therapy Market, by Key Country – Revenue (2022) (US$ Million)
Figure 19. North America Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 20. North America Lung Cancer Therapy Market, By Key Countries, 2022 and 2030 (%)
Figure 21. US Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 22. Canada Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 23. Mexico Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 24. Europe Lung Cancer Therapy Market, by Key Country – Revenue, 2022 (US$ Million)
Figure 25. Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 26. Europe Lung Cancer Therapy Market, By Key Countries, 2022 and 2030 (%)
Figure 27. UK Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 28. Germany Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 29. France Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 30. Italy Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 31. Spain Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 32. Russia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 33. Rest of Europe Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 34. Asia Pacific Lung Cancer Therapy Market, by Key Country – Revenue, 2022 (US$ Million)
Figure 35. Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 36. Asia Pacific Lung Cancer Therapy Market, By Key Countries, 2022 and 2030 (%)
Figure 37. China Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 38. Japan Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 39. India Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 40. Australia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 41. South Korea Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 42. Southeast Asia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 43. Singapore Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 44. Malaysia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 45. Indonesia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 46. Vietnam Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 47. Cambodia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 48. Philippines Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 49. Rest of Southeast Asia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 50. Rest of Asia Pacific Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 51. Middle East & Africa Lung Cancer Therapy Market, by Key Country – Revenue, 2022 (US$ Million)
Figure 52. Middle East & Africa Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 53. Middle East & Africa Lung Cancer Therapy Market, By Key Countries, 2022 and 2030 (%)
Figure 54. Saudi Arabia Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 55. South Africa Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 56. UAE Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 57. Rest of Middle East Africa Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 58. South & Central America Lung Cancer Therapy Market, by Key Country – Revenue, 2022 (US$ Million)
Figure 59. South & Central America Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 60. South & Central America Lung Cancer Therapy Market, By Key Countries, 2022 and 2030 (%)
Figure 61. Brazil Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 62. Argentina Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 63. Rest of South & Central America Lung Cancer Therapy Market Revenue and Forecast to 2030 (US$ Mn)
Figure 64. Growth Strategies in Lung Cancer Therapy Market

The List of Companies – Lung Cancer Therapy Market
o Medtronic PLC
o RF Medical Co Ltd
o Johnson & Johnson
o Merck KGaA
o Sun Pharmaceutical Industries Ltd
o Bioventus Inc
o Meiji Seika Pharma Co Ltd
o Advanz Pharma Corp
o Olympus Corp

Reviews

There are no reviews yet.

Be the first to review “Lung Cancer Therapy Market Size and Forecasts (2020-2030)”

You must be logged in to post a review.